Literature DB >> 17075227

The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage.

John Keeling1, Guillermo A Herrera.   

Abstract

Certain structurally abnormal light and heavy chains are known to be nephrotoxic and alter mesangial homeostasis producing pathological alterations. Many of the mechanisms involved in light chain-mesangial interactions have been deciphered using an in vitro model, providing a framework for understanding the sequence of events that leads to irreversible glomerular changes and eventually renal failure. The molecular events involved in the pathogenesis of these disorders are now for the most part well-established. These studies have delineated the sequence of steps involved and crucial events have been determined. An animal model is being developed which will undoubtedly contribute significantly to validate the information that has been obtained from the in vitro models. The present chapter will address the pathogenesis of these disorders with an emphasis on highlighting crucial steps possibly amenable to therapeutic intervention to stop or ameliorate adverse consequences leading to irreversible changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17075227     DOI: 10.1159/000096764

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  5 in total

1.  Treatment of light chain deposition disease with bortezomib and dexamethasone.

Authors:  Efstathios Kastritis; Magdalini Migkou; Maria Gavriatopoulou; Panos Zirogiannis; Valsamakis Hadjikonstantinou; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

2.  Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy.

Authors:  Maria Teresa Rocchetti; Massimo Papale; Anna Maria d'Apollo; Ida Valentina Suriano; Anna Maria Di Palma; Grazia Vocino; Eustacchio Montemurno; Leonarda Varraso; Giuseppe Grandaliano; Salvatore Di Paolo; Loreto Gesualdo
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

3.  Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.

Authors:  Colin A Hutchison; Stephen Harding; Pete Hewins; Graham P Mead; John Townsend; Arthur R Bradwell; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

4.  Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report.

Authors:  Abdul Moiz; Tariq Javed; Jorge Garces; Catherine Staffeld-Coit; Paisit Paueksakon
Journal:  Ochsner J       Date:  2014

5.  Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling.

Authors:  Guillermo A Herrera; Luis Del Pozo-Yauner; Jiamin Teng; Chun Zeng; Xinggui Shen; Takahito Moriyama; Veronica Ramirez Alcantara; Bing Liu; Elba A Turbat-Herrera
Journal:  Kidney Int Rep       Date:  2021-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.